-
公开(公告)号：EP3437661A1
公开(公告)日：2019-02-06
申请号：EP18179965.1
申请日：2009-10-16
申请人： Baxalta GmbH , Baxalta Incorporated
摘要： The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.
-
公开(公告)号：EP3323430A1
公开(公告)日：2018-05-23
申请号：EP17196565.0
申请日：2007-12-14
申请人： Baxalta GmbH , Baxalta Incorporated
CPC分类号： A61K38/4846 , A61K47/549 , A61K47/61 , C12N9/6437 , C12N9/96 , C12Y304/21021 , Y02A50/463
摘要： The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (F Vila) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
-
3.发明授权Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life 有权具有延长的体内半衰期的因子VIIa-（聚）唾液酸偶联物
公开(公告)号：EP2532369B1
公开(公告)日：2017-11-01
申请号：EP12004951.5
申请日：2007-12-14
申请人： Baxalta GmbH , Baxalta Incorporated
CPC分类号： A61K47/4823 , A61K38/4846 , A61K47/549 , A61K47/61 , C12N9/6437 , C12N9/96 , C12Y304/21021 , Y02A50/463
摘要： The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (F VIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
-
公开(公告)号：EP3495488A1
公开(公告)日：2019-06-12
申请号：EP18202001.6
申请日：2009-10-27
申请人： Baxalta GmbH , Baxalta Incorporated
IPC分类号： C12N15/85 , A01K67/027 , A61K49/00
摘要： The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.
-
公开(公告)号：EP3808378A1
公开(公告)日：2021-04-21
申请号：EP20197463.1
申请日：2012-05-25
申请人： Baxalta GmbH , Baxalta Incorporated
摘要： The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.
-
6.发明公开GLYCOPOLYSIALYLATION OF PROTEINS OTHER THAN BLOOD COAGULATION PROTEINS 审中-公开葡萄糖ON ON ON ON EN EN EN EN EN EN EN EN EN EN EN EN
公开(公告)号：EP3081233A1
公开(公告)日：2016-10-19
申请号：EP16168473.3
申请日：2010-07-26
发明人： Jain, Sanjay , Gregoriadis, Gregory , Dwivedi, Archana , Nath, Srijit , Siekmann, Juergen , Haider, Stefan , Rottensteiner, Hanspeter , Turecek, Peter
IPC分类号： A61K47/48
CPC分类号： A61K47/6455 , A61K47/60 , A61K47/61 , A61K47/65
摘要： A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.
摘要翻译： 将水溶性聚合物，特别是聚唾液酸（PSA）或修饰的PSA（mPSA）与不同于凝血蛋白的糖蛋白的氧化碳水化合物部分缀合或通过使氧化的碳水化合物部分接触而与神经节苷脂或药物递送系统 其中所述水溶性聚合物含有氨基氧基，并且在水溶性聚合物上的氧化碳水化合物部分和氨基氧基之间形成肟键，或者其中所述水溶性聚合物含有酰肼基，腙键是 形成在水溶性聚合物上的氧化碳水化合物部分和酰肼基团之间。 因此得到氨基氧基或酰肼 - 水溶性聚合物如PSA和mPSA的结合物，其中PSA或mPSA通过碳水化合物部分连接。
-
公开(公告)号：EP3412314A1
公开(公告)日：2018-12-12
申请号：EP18182890.6
申请日：2012-05-25
申请人： Baxalta GmbH , Baxalta Incorporated
摘要： The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.015 秒)
